Biolexis Therapeutics Inc. is working on developing orally available, small-molecule AMPK activators that have been found to stimulate AMPK activity as well as dose-dependently enhance glucose uptake ...
Biolexis Therapeutics Inc. has identified AMP-activated protein kinase (AMPK) activators reported to be useful for the treatment of diabetes, ischemia-reperfusion injury, dyslipidemia, obesity, ...
BOSTON--(BUSINESS WIRE)--Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a biotechnology company that designs and develops breakthrough medicines for patients through its powerful ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results